A randomized phase III trial of Palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Erica L. Mayer, MD, PhD (Dana-Farber Cancer Institute)
Angela DeMichele, MD (University of Pennsylvania)
Michael Gnant, MD (Medical University, Viena)